Sinopharm Tech Holdings Ltd. (stock code 08156) has filed its resubmitted monthly return for the period ended 30 April 2026, confirming a stable capital structure with no movements in issued ordinary shares or convertible preference shares during the month. Key data points are as follows:

1. Authorised Capital • Total authorised capital remained unchanged at HKD 200.00 million, divided into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares, each with a par value of HKD 0.0125. • The structure reflects the November 2024 capital reorganisation that split each HKD 0.3125 share into 25 shares of HKD 0.0125.

2. Issued Share Capital and Public Float • Ordinary shares in issue: 633.69 million (no change versus March 2026). • Treasury shares: Nil, leaving total issued ordinary shares unchanged at 633.69 million. • Public float: 24.95 % of issued ordinary shares, satisfying Hong Kong listing requirements.

3. Convertible Preference Shares • Outstanding convertible preference shares: 1.48 billion, unchanged month-on-month. • Conversion price: HKD 0.10 per share, with a 1:1 conversion ratio into ordinary shares available at any time until November 2034.

4. Share Option Scheme Activity • 2021 Share Option Scheme: 120,000 options lapsed in April. • Outstanding options: 4.96 million, exercisable at an adjusted price of HKD 1.00. • No new ordinary shares were issued from option exercises; total potential dilution from all outstanding options stands at 4.96 million shares, with an additional 12.42 million options still available for future grant.

5. Other Instruments and Corporate Actions • No warrants, other convertibles, or agreements to issue additional shares were reported for the month. • No Hong Kong Depositary Receipts or treasury share movements occurred.

The filing, signed by Executive Director Ms. Kwok Shuk Yi on 7 October 2026, affirms compliance with all applicable Hong Kong Stock Exchange listing rules and public float requirements.